Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells

[1]  R. Perez-soler,et al.  Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. , 2002, Molecular pharmacology.

[2]  K. Fung,et al.  Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: inhibition of proliferation and induction of apoptosis. , 2002, Life sciences.

[3]  M. Tallman,et al.  Acute promyelocytic leukemia: evolving therapeutic strategies. , 2002, Blood.

[4]  Guoqiang Chen,et al.  Arsenic trioxide, a therapeutic agent for APL , 2001, Oncogene.

[5]  G. Chan,et al.  Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2 , 2001, The Journal of cell biology.

[6]  M. Hoyt,et al.  A new view of the spindle checkpoint , 2001, The Journal of cell biology.

[7]  T. Kwon,et al.  Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. , 2001, Biochemical and biophysical research communications.

[8]  Liying Wang,et al.  Arsenic‐induced NFκβ transactivation through Erks‐ and JNKs‐dependent pathways in mouse epidermal JB6 cells , 2001, Molecular and Cellular Biochemistry.

[9]  I. Weissman,et al.  Bcl-2 Cooperates with Promyelocytic Leukemia Retinoic Acid Receptor α Chimeric Protein (Pmlrarα) to Block Neutrophil Differentiation and Initiate Acute Leukemia , 2001, The Journal of experimental medicine.

[10]  S. Yuen,et al.  Arsenic trioxide induces apoptosis in human gastric cancer cells through up‐regulation of P53 and activation of caspase‐3 , 2001, International journal of cancer.

[11]  Catherine G. Takizawa,et al.  Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. , 2000, Current opinion in cell biology.

[12]  Y. Huang,et al.  Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia , 2000, Leukemia.

[13]  G. Kroemer,et al.  Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. , 1999, Experimental cell research.

[14]  Jonathan D. Licht,et al.  Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia , 1999 .

[15]  J. Larghero,et al.  Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. , 1999, Cancer research.

[16]  F. Mandelli,et al.  Acute promyelocytic leukemia: a curable disease , 1998, Leukemia.

[17]  A. Kumagai,et al.  The Xenopus Chk1 Protein Kinase Mediates a Caffeine-sensitive Pathway of Checkpoint Control in Cell-free Extracts , 1998, The Journal of cell biology.

[18]  C. Niu,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. , 1997, Blood.

[19]  T. Ley,et al.  Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. , 1997, Blood.

[20]  Z. Darżynkiewicz,et al.  Discrimination of G2 and mitotic cells by flow cytometry based on different expression of cyclins A and B1. , 1995, Experimental cell research.

[21]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[22]  Christine Chomienne,et al.  The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.

[23]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[24]  G. Webster,et al.  Biological activity of reconstituted ribosomes. , 1960, Experimental cell research.

[25]  S. Shi.  Use of Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia , 2002 .

[26]  Zhen-yi Wang,et al.  Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide , 2001 .

[27]  J. Spivak,et al.  Commentary on and reprint of Huang M-E, Ye Y-C, Chen S-R, Chai J-R, Lu J-X, Zhoa L, Gu L-J, Wang Z-Y, Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia, in Blood (1988) 72:567–572 , 2000 .

[28]  Yong-kui,et al.  Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. , 1999, Journal of the National Cancer Institute.

[29]  J. Licht,et al.  Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. , 1999, Blood.